Abstract
Lombardy is one of the regions in Italy most affected by COVID-19. We assessed the diffusion of the virus via testing plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees of 7 different hospitals, located across the Lombardy region in areas with different exposure to the epidemic. Subjects filled an anamnestic questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-19-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical area where the hospital was located and ranged between 3 to 43% which correlated with the incidence of COVID-19 in Lombardy. There was a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. We observed 10% of IgG positive asymptomatic individuals and another 20% with one or two symptoms. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected. IgG positivity correlated with family contacts. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and to extra-hospital exposure.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04387929
Funding Statement
The study was funded by the Italian Ministry of Health (Ricerca Corrente)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Istituto clinico Humanitas and Humanitas Gavazzeni Ethical committees approved the protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request
